Cell Therapy

News

Sanofi to acquire Kiadis and NK cell tech for $353 million

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million).

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Bayer buys cell & gene therapy firm AskBio for $4 billion

Bayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US biotech Asklepios BioPharmaceutical, also known as AskBio.

News

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, just in time to meet a contingent value right (CVR) due to Celgene shareholde

Events

Partner Content

2nd Macrophage-directed Therapies Summit

Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond

Events

Partner Content

Patient-to-Patient Supply for Cell Immunotherapies Summit

Achieving Standardization & Operational Excellence in Vein-to-Vein Supply

News

Kiadis shares yo-yo on cell therapy trial for COVID-19

Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains o

Sanofi to acquire Kiadis and NK cell tech for $353 million

Bayer buys cell & gene therapy firm AskBio for $4 billion

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

2nd Macrophage-directed Therapies Summit

Patient-to-Patient Supply for Cell Immunotherapies Summit

Kiadis shares yo-yo on cell therapy trial for COVID-19

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Cell Therapy

Editor's Picks